论文部分内容阅读
目的:探讨C-erbB-2,p53,雌激素受体(estrogen receptor,ER)、孕激素受体(progesterone receptor,PR)在乳腺癌中的表达及临床价值。方法:采用免疫组织化学SP法检测246例乳腺癌组织及其癌旁正常乳腺组织中C-erbB-2,p53,ER和PR蛋白的表达情况。结果:在246例乳腺癌中,C-erbB-2,p53,ER和PR的阳性表达率分别为77.6%,73.6%,63.0%和57.7%;C-erbB-2和p53阳性表达率在不同临床分期、有无淋巴结转移上差异有统计学意义(P<0.05);C-erbB-2,p53,ER和PR阳性表达率在不同肿瘤大小上差异无统计学意义(P>0.05)。结论:联合检测乳腺癌C-erbB-2,p53,ER和PR对判断预后和治疗有指导价值。
Objective: To investigate the expression and clinical value of C-erbB-2, p53, estrogen receptor (ER) and progesterone receptor (PR) in breast cancer. Methods: The expressions of C-erbB-2, p53, ER and PR in 246 cases of breast cancer tissues and adjacent normal breast tissues were detected by immunohistochemical SP method. Results: The positive rates of C-erbB-2, p53, ER and PR in 77 cases of breast cancer were 77.6%, 73.6%, 63.0% and 57.7% respectively. The positive rates of C-erbB-2 and p53 were different There was significant difference in clinical stage and lymph node metastasis (P <0.05). The positive rate of C-erbB-2, p53, ER and PR in different tumor size had no statistical significance (P> 0.05). Conclusions: The combined detection of C-erbB-2, p53, ER and PR in breast cancer has guiding value in the prognosis and treatment.